LCM
GYRE icon

Laurion Capital Management’s Gyre Therapeutics GYRE Stock Holding History

Laurion Capital Management’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-2,533
Closed -$112K – 958
2020
Q2 		$112K Buy
+2,533
New +$119K ﹤0.01% 816

Other funds holding GYRE

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Laurion Capital Management's GYRE Position: Q3 2020 in Review

Laurion Capital Management sold out of Gyre Therapeutics (GYRE) in Q3 2020, closing a stake of 2,533 shares — an estimated $112K sold.

Laurion Capital Management first reported a position in GYRE in Q2 2020 and held it in 1 quarter. The position peaked at $112K in Q2 2020. 78 funds tracked by Wall St. Rank hold GYRE as of Q3 2020.

  • Laurion Capital Management reported no remaining Gyre Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Laurion Capital Management sold 2,533 Gyre Therapeutics shares in Q3 2020, an estimated $112K.
  • Laurion Capital Management first reported a position in Gyre Therapeutics in Q2 2020 and held it in 1 quarter.
  • Laurion Capital Management's Gyre Therapeutics position peaked at $112K in Q2 2020.
  • 78 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q3 2020.

Based on Laurion Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.